- Home
- AMAC vs AMRN Comparison
AMAC vs AMRN Comparison
Compare AMAC & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAC | AMRN |
|---|---|---|
| Founded | 2025 | 1989 |
| Country | Cayman Islands | Ireland |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.7M | 287.9M |
| IPO Year | 2026 | 1998 |
Fundamental Metrics
Financial Performance| Metric | AMAC | AMRN |
|---|---|---|
| Price | $9.80 | $11.67 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 44.8K | ★ 60.2K |
| Earning Date | N/A | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $9.79 | $11.25 |
| 52 Week High | $9.82 | $20.90 |
Technical Indicators
Market Signals| Indicator | AMAC | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 50.03 | 25.75 |
| Support Level | $9.79 | N/A |
| Resistance Level | $9.81 | $15.34 |
| Average True Range (ATR) | 0.01 | 0.35 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 50.25 | 13.13 |
Price Performance
Historical ComparisonAbout AMAC AMR Resources Acquisition Corp Class A Ordinary Shares
AMR Resources Acquisition Corp is a newly formed blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more operating businesses.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.